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Abstract
Background: As only a minor portion of the information present in histological sections is accessible by eye,
recognition and quantification of complex patterns and relationships among constituents relies on digital image
analysis. In this study, our working hypothesis was that, with the application of digital image analysis technology,
visually unquantifiable breast cancer microarchitectural features can be rigorously assessed and tested as prognostic
parameters for invasive breast carcinoma of no special type.
Methods: Digital image analysis was performed using public domain software (ImageJ) on tissue microarrays from a
cohort of 696 patients, and validated with a commercial platform (Visiopharm). Quantified features included elements
defining tumour microarchitecture, with emphasis on the extent of tumour-stroma interface. The differential prognostic
impact of tumour nest microarchitecture in the four immunohistochemical surrogates for molecular classification was
analysed. Prognostic parameters included axillary lymph node status, breast cancer-specific survival, and time to distant
metastasis. Associations of each feature with prognostic parameters were assessed using logistic regression
and Cox proportional models adjusting for age at diagnosis, grade, and tumour size.
Results: An arrangement in numerous small nests was associated with axillary lymph node involvement. The
association was stronger in luminal tumours (odds ratio (OR) = 1.39, p = 0.003 for a 1-SD increase in nest number,
OR = 0.75, p = 0.006 for mean nest area). Nest number was also associated with survival (hazard ratio (HR) = 1.
15, p = 0.027), but total nest perimeter was the parameter most significantly associated with survival in luminal
tumours (HR = 1.26, p = 0.005). In the relatively small cohort of triple-negative tumours, mean circularity showed
association with time to distant metastasis (HR = 1.71, p = 0.027) and survival (HR = 1.8, p = 0.02).
Conclusions: We propose that tumour arrangement in few large nests indicates a decreased metastatic potential. By
contrast, organisation in numerous small nests provides the tumour with increased metastatic potential to regional lymph
nodes. An outstretched pattern in small nests bestows tumours with a tendency for decreased breast cancer-specific
survival. Although further validation studies are required before the argument for routine quantification of
microarchitectural features is established, our approach is consistent with the demand for cost-effective methods for
triaging breast cancer patients that are more likely to benefit from chemotherapy.
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Background
Breast cancer is the most common cancer in the UK,
with a lifetime risk around 1 in 8 women [1]. Although a
sustained decline in mortality has been observed, mainly
due to population screening and adjuvant systemic therapy
[2], breast cancer is still the third most common cause of
cancer death in the UK [1].
Pathological assessment is the gold standard for surgical
and oncological treatment decision making, as tumour
morphology remains the strongest predictor of clinical
outcome and the financially and practically preferred
option [3, 4]. In view of the evidence on its prognostic sig-
nificance, the recent eighth edition of the primary tumour,
lymph node, and metastasis classification of the American
Joint Commission of Cancer introduced assessment of
tumour grade into the breast cancer staging system [5],
giving credit to the validity of this long-standing practice.
However, the existence of a subjective element in the
implementation of the currently employed Elston-Ellis
modification of the Scarff-Bloom-Richardson grading sys-
tem has been recognised [6, 7]. A mere five-gene signature
can separate grade 2 tumours, the subset with the lowest
degree of concordance [7], into two classes with signifi-
cantly different metastatic potential [8]. Regarding tumour
type, three-quarters of invasive breast carcinomas are
categorised as no special type (NST) [9], a heterogeneous
group of tumours that fail to exhibit sufficient characteris-
tics to achieve classification as a specific histologic type,
such as tubular or mucinous carcinoma. Unlike special
type carcinomas that are associated with distinct prognosis,
NST carcinomas show variable outcome and more hetero-
geneous molecular profile. Therefore, novel prognostic
identifiers are needed for a more informative stratification,
especially of grade 2 invasive carcinomas NST. This will po-
tentially increase significantly the accuracy of determining
the group of patients who are more likely to profit from
systemic adjuvant treatment [10].
As only a minor portion of the vast amount of infor-
mation present in histological sections is accessible by
eye, recognition and quantification of complex patterns
and relationships among constituents relies on computer-
aided quantitative digital image analysis (DIA). This
approach has the potential to go beyond automation and
standardisation of established morphological parameters
[11–13]. In histological sections, a tumour can be studied
along its microenvironment, and observations on spatial
inter-relationships among several components can be
addressed. However, despite its conceptual advantage in
cancer histomorphometry, DIA is still in its infancy and,
as discussed in detail below, only a few related papers have
been published.
The working hypothesis for our study was that, with the
application of DIA technology, previously unquantifiable
breast cancer microarchitectural features can be rigorously
assessed in detail and tested as prognostic parameters for
invasive carcinomas NST. Special attention was given to
conceivable differences in the four subgroups deriving
from expression of oestrogen receptor (ER) and human
epidermal growth factor receptor 2 (HER2). Quantified
features included elements defining the extent of tumour-
stroma interface, the arena of tumour-stroma interactions
implicated as determinants of cancer progression. In
addition, features reflecting the remarkably variable micro-
geometry of invasive carcinomas NST were analysed. The
biological rationale for pursuing these features was based
on studies in experimental models implicating the micro-
architectural arrangement of breast cancer cells as an indi-
cator of their transcriptomic profile [14] and a predictor of
their kinetic behaviour and metastatic predilection [15].
The selected prognostic parameters included axillary
lymph node status, breast cancer-specific survival (BCSS),
and time to distant metastasis (TTDM).
To test the hypothesis, DIA was initially performed
using the public domain software ImageJ [16–18] on tissue
microarrays (TMAs) constructed from a cohort of breast
cancer patients, and was subsequently validated by
assessing concordance with the Visiopharm commercial
image analysis platform [19].
Methods
Participants
A cohort of 957 adult breast cancer patients with clinical,
histopathological, and outcome data was collated in
Nottingham between 1987 and 1998. TMAs were as-
sembled using archival diagnostic formalin-fixed
paraffin embedded tumour blocks from patients in
the cohort as previously described [20]. In the current
study, we included breast cancer patients aged 70 years or
less presenting with operable ductal NST or mixed NST
and special type carcinomas. Subtyping of mixed tumours
was compliant with the criteria endorsed by the World
Health Organisation (WHO) and the UK guidelines that
require 90% purity of special type components to diagnose
the tumour into a special type category. Special types of
breast cancer that have distinct prognosis, including pure
tubular carcinomas, were excluded. All patients were
assessed in a standardised method considering clinical his-
tory and tumour characteristics, and were accordingly
triaged for adjuvant hormone therapy and chemotherapy.
Survival data were collected prospectively and included
BCSS, defined as the interval from the date of primary
treatment to the time of death because of breast cancer,
and TTDM, defined as the interval from the date of pri-
mary treatment to the first distant recurrence. Data were
successfully extracted from the TMAs for 696 patients
meeting the above inclusion criteria (474 ductal NST, 173
tubular/NST mixed, 32 lobular/NST mixed, and 17 other
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special type/NST mixed), and the image acquisition and
analysis criteria (see below).
Immunohistochemistry
TMA sections were stained with cytokeratin 7/8
immunohistochemistry to highlight tumour cells and
counterstained with haematoxylin as described
previously [20].
Image acquisition
Digitised images of the slides were acquired using the
high-resolution digital scanner (NanoZoomer; Hamamatsu
Photonics, Welwyn Garden City, UK). Slides were scanned
at × 20 magnification and images were saved in the NDPI
format. For the initial analysis, virtual slides were opened
in the NDP.view 2 software (Hamamatsu) and individual
tissue spots were exported as JPEG (8-bit) files at × 100
magnification (1272 × 944 pixels). Cut-out spots and spots
with < 50% remaining tissue were excluded from the image
analysis. For the validation stage, TMA whole slides were
opened in the VIS software package (Visiopharm) and
de-arrayed into spots using the Tissuearray module.
Image analysis
The initial image analysis was carried out using the Fiji
package of ImageJ (NIHR public domain). Individual tissue
spot JPEG files were imported into ImageJ and the image
was split into RBG channels. The image segmentation of
tumour from non-tumour was carried out on the blue
colour space; the red and green channels were discarded.
The segmentation to identify objects of interest was car-
ried out by adjusting the greyscale data to a binary image
with foreground pixels of interest set to black (pixel signal
intensity of 0) and background pixels set to white
(maximum 8-bit intensity of 255). The pixel intensity
threshold for classifying all pixels as either foreground or
background was defined automatically using the ImageJ
histogram thresholding feature. TMA spots with weak or
no immunohistochemical staining (therefore not
segmented successfully with thresholding) were excluded
from the study at this point. Objects of interest (particles)
were identified as any co-localised foreground pixels (i.e.
adjacent pixels with no intervening background) with a
particle size (pixels2) set between 30 and infinity. A cut-off
of 30 was taken as this is slightly greater than the area of a
single cell since our aim was to include all tumour cell ag-
gregates (“nests”) ranging between single cell and large
groups that involved the major part of the TMA spot area.
Any particles with a size < 30 were discarded as
background (set to 255). Internal object holes (areas of
background within objects, e.g. tumour nests with central
lumina) were filled and thus included as forming a part of
any particle in which they were found. Features were
extracted by measuring the pixel numbers for any particles
in the final image. Features extracted included number of
particles present in the image (taken to be the number of
tumour nests), combined particle surface area in total
pixels (taken to be the total tumour surface area), mean
particle size in pixels (taken to be the average tumour nest
size), combined perimeter in pixels (the number of pixels
forming the one pixel thick border of any particle) for
all particles (taken to be the total tumour perimeter),
mean particle circularity (4π(area/perimeter2))—an
ImageJ in-built function which is stated to equate to
particle smoothness (taken to be the average nest
perimeter smoothness)—and mean particle roundnes-
s—also an ImageJ function which is a ratio of longest
diameter to shortest diameter in pixels of any particle
(taken to be the average roundness of a tumour nest).
Data points were recorded in pixels and exported to
Microsoft Excel alongside clinical outcome data.
Statistical analysis
Associations of each feature with lymph node involvement
were assessed using logistic regression adjusting for age at
diagnosis, grade, and tumour size. Associations of each
feature with survival and with distant metastasis were
assessed using Cox proportional hazards models adjusted
for age at diagnosis, grade, and tumour size. We used the
imaging variables both as numeric to yield estimates per 1
unit or per 1 standard deviation (SD) increase, where
appropriate, and as categorical to assess the shape of the
associations, grouped in tertiles such that there was a
sufficient number of observations in each group. For ana-
lysis of associations between tumour microarchitectural
features with BCSS and TTDM, only cases that did not re-
ceive chemotherapy were selected. For BCSS, individuals
were censored at last follow-up. For TTDM, individuals
were censored at the latest date known to be alive and free
of distant metastasis. Analyses were repeated in subgroups
defined by ER and HER2 status and in subgroups defined
by tumour grade. Features were used both as categorical
and as numeric variables, log transformed where
appropriate. Analyses were performed using R [21].
Tumour microarchitectural features quantified by
ImageJ and by Visiopharm were compared by inspecting
scatterplots and correlation coefficients.
Results
Data were successfully extracted from the TMAs of 696
patients as described in the Methods section. From the 656
cases with known ER and HER2 status, 72% were ER
+/HER2–, 9% ER+/HER2+, 8% ER–/HER2+ and 11% were
ER–/HER2–. The mean age at diagnosis was 53.5 years and
the mean tumour size was 20.3 mm. From the 667 patients
with available information on the axillary lymph node
status at the time of operation, 286 patients (43%) had at
least one involved lymph node and 381 had clear axilla.
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During the postoperative follow-up period, 242 died from
breast cancer, 319 were alive, and 106 died from unrelated
or unknown causes. From the 664 patients with available
information, 258 patients developed distant metastasis
whereas 406 did not.
In the complete cohort, tumour grade was associated
with lymph node status adjusting for age and tumour
size (adjusted odds ratio (OR) per unit increase 1.28,
p = 0.035). It was a very strong predictor for breast
cancer-specific death (adjusted hazard ratio (HR) per unit
increase 1.69, p = 1.9 × 10–6) and distant metastasis
(adjusted HR = 1.64, p = 2.1 × 10–6) in individuals who did
not receive chemotherapy.
In the complete cohort, tumour size was significantly
associated with lymph node status adjusting for age and
tumour grade (adjusted OR = 1.97, p = 2.9 × 10–9). It was
also strongly associated with breast cancer-specific death
(adjusted HR per 1 cm increase 1.39, p = 1.2 × 10–8) and
distant metastasis (adjusted HR = 1.49, p = 2.2 × 10–6) in
individuals who did not receive chemotherapy.
Microarchitectural features and lymph node status
In this study, the prognostic significance of multiple
features assessed using image analysis was evaluated and
this included number of tumour nests, mean nest area and
perimeter, total nest perimeter, and others as follows.
Number of nests
Multivariable logistic regression analysis in the complete
cohort showed an association of number of nests with
lymph node status adjusting for grade and tumour size.
Higher number of nests was associated with positive
lymph node status (OR per 1 SD 1.21, 95% confidence
interval (CI) 1.02 to 1.42; p = 0.025). In the ER+/HER2–
subgroup, the association was stronger compared to the
whole cohort (mean 100 in lymph node positive versus
80.5 in lymph node negative cases; OR per 1 SD increase
1.39, 95% CI 1.12 to 1.72; p = 0.003). The association in
the ER+/HER2– subgroup was significant in grade 2
tumours (OR per 1 SD 1.43, 95% CI 1.06 to 1.91; p =
0.018; Figs. 1a and 2) and borderline significant in grade
1 tumours (OR per 1 SD 1.83, 95% CI 0.94 to 3.56, p =
0.073). In grade 3 tumours there was no significant asso-
ciation. The other three subgroups derived from ER/
HER2 combinations showed no significant associations
between number of nests and nodal status.
Mean nest area
Multivariable logistic regression analysis in the complete
cohort showed that mean nest area was borderline
significantly associated with lymph node status (OR per
1 SD higher log(mean area): 0.85, 95% CI 0.72 to 1.01; p
= 0.06). Higher mean nest area was associated with
negative lymph node status in the ER+/HER2– subgroup
(OR per 1 SD higher log(mean area): 0.75, 95% CI 0.61
to 0.92; p = 0.006), and the association was even stronger
in the grade 2 ER+/HER2– subgroup (mean 1253 in
lymph node positive versus 2928 in lymph node negative
cases, OR per 1 SD higher in log(mean area): 0.59, 95%
CI 0.42 to 0.84; p = 0.003; Figs. 1b and 2).
Mean and total nest perimeter
Like mean nest area, mean nest perimeter was borderline
significantly associated with lymph node status in the
complete cohort (OR per 1 SD higher log(mean perimeter):
0.85, 95% CI 0.72 to 1.01; p = 0.06). Higher mean nest
perimeter was associated with negative lymph node status
in the ER+/HER2– subgroup (OR per 1 SD higher
log(mean perimeter): 0.77, 95% CI 0.63 to 0.94; p = 0.01),
and the association was even stronger in the grade 2 ER
+/HER2– subgroup (OR 1 SD higher log(mean perimeter):
0.60, 95% CI 0.43 to 0.85; p = 0.003; Fig. 1c). In this study,
the total nest perimeter was not associated with lymph
node status.
Fig. 1 Microarchitectural features and axillary lymph node status in grade 2 ER+/HER2– invasive carcinomas NST and mixed NST/special subtype.
a Number of nests, b mean nest area, and c mean nest perimeter
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Other features
Multivariable logistic regression analysis in the whole
cohort showed an association between mean nest round-
ness and lymph node status adjusting for grade and
tumour size. Higher nest roundness was associated with
positive lymph node status (OR 1.21, 95% CI 1.02 to
1.42; p = 0.033). This correlation was even stronger in
grade 2 tumours (OR 1.72, 95% CI 1.25 to 2.37; p = 0.0008).
Mean circularity was borderline significantly associated
with lymph node status in the whole cohort (OR 1.18,
95% CI 1 to 1.4; p = 0.052) and stronger associated in
grade 2 tumours (OR 1.40, 95% CI 1.03 to 1.9; p = 0.029).
Total tumour area was not associated with lymph
node status, survival, or time to distant metastasis.
Microarchitectural features and breast cancer-specific
survival
Number of nests
Analysis of the whole cohort using Cox proportional haz-
ard models adjusted for grade and tumour size showed an
association between number of nests and BCSS. A higher
number of nests was associated with a lower survival (HR
1.15, 95% CI 1.02 to 1.31; p = 0.027). The association was
significant only in the ER+/HER2– subgroup (HR 1.19,
95% CI 1.02 to 1.38; p = 0.023; Fig. 3a). Interestingly, it
was borderline significant in grade 1 tumours (HR 1.71,
95% CI 0.97 to 3.01; p = 0.06), and in this subset tumour
size was not significantly associated with BCSS (HR 1.57,
95% CI 0.91 to 2.69; p = 0.1), but the size of this subset
was relatively small (n = 108).
In the triple-negative subgroup (ER–/HER2–), the
number of nests showed a certain trend (HR 1.45, 95%
CI 0.96 to 2.18; p = 0.078; Fig. 4a), whereas grade and
tumour size showed no prognostic correlation with
survival (both p = 0.2) in this relatively small subset (n =
69). HER2+ tumours did not show analogous trend (HR
0.84, p = 0.49 in ER+/HER2+ and HR 1.01, p = 1.05 in
ER–/HER2+).
Mean nest area and mean nest perimeter
Mean nest area and mean nest perimeter were not
associated with BCSS.
Fig. 2 Microarchitectural features and axillary lymph node status in grade 2 ER+/HER2– invasive carcinomas NST and mixed NST/special subtype.
a 21-mm tumour with axillary lymph node involvement at presentation; nest number = 136, mean nest area = 1132. b 25-mm tumour without
lymph node involvement at presentation; nest number = 28, mean nest area = 3935
Fig. 3 Kaplan-Meier curves of BCSS in ER+/HER2– invasive carcinomas NST and mixed NST/special subtype. High number of nests (a) and total
nest perimeter (b) are associated with decreased BCSS
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Total nest perimeter
Analysis of the whole cohort of patients who did not re-
ceive chemotherapy using Cox proportional hazard models
adjusted for grade and tumour size showed an association
between total nest perimeter and BCSS. Higher total nest
perimeter was associated with a lower survival probability
(HR per 1 SD higher log(total perimeter) = 1.22, 95% CI
1.07 to 1.39; p = 0.003). This association was only seen in
the ER+/HER2– subset (HR per 1 SD higher log(total
perimeter) = 1.26, 95% CI 1.07 to 1.49; p = 0.005; Figs. 3b
and 5) with magnitude of association strength comparable
to grade (HR = 1.45, 95% CI 1.13 to 1.87; p = 0.003) and size
(HR = 1.54, 95% CI 1.26 to 1.89; p = 2.6 × 10–5).
Other features
In the triple-negative subgroup (ER–/HER2–), mean cir-
cularity was associated with BCSS. Higher nest circular-
ity was associated with a lower survival (HR = 1.8, 95%
CI 1.09 to 2.96, p = 0.02), whereas grade only reached a
borderline association (p = 0.048) and tumour size
showed no prognostic correlation (p = 0.67) with survival
in this subset.
Microarchitectural features and time to distant metastasis
Using Cox proportional hazards models adjusted for
grade and tumour size, there was a significant associ-
ation between number of nests and TTDM in grade 1
tumours (HR per 1 SD increase 1.84, 95% CI 1.05 to
3.21; p = 0.03; Fig. 6), a subgroup of patients where
tumour size did not show such an association (HR 1.13,
p = 0.67).
Similar to BCSS, triple-negative cancers showed a
trend for cases with higher number of nests to present
with higher risk of distant metastasis (HR per 1 SD in-
crease 1.45, 95% CI 0.98 to 2.15; p = 0.06; Fig. 4b). Also
similar to BCSS, mean circularity was associated with
TTDM (HR 1.71, 95% CI 1.06 to 2.74, p = 0.027),
whereas grade and tumour size were only borderline sig-
nificantly associated (p = 0.07 and p = 0.06, respectively)
with TTDM in this subset.
Fig. 4 Kaplan-Meier curves of BCSS and TTDM in triple-negative invasive carcinomas NST and mixed NST/special subtype. High number of nests
showed a certain trend for decreased BCSS (a) and TTDM (b)
Fig. 5 Total nest perimeter association with BCSS in ER+/HER2– invasive carcinomas NST and mixed NST/special subtype. a 22-mm grade 3
tumour with total nest perimeter = 19,458; patient died from breast cancer in 19 months postoperatively. b 22-mm grade 3 tumour with total
nest perimeter = 8183; patient alive after 216 months of follow-up
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The features extracted from ImageJ were highly corre-
lated to the values obtained using Visiopharm. Pearson’s
correlation coefficients ranged from 0.74 to 0.98.
Discussion
In this study, we used a public domain image processing
program as a tool for analysing and quantifying micro-
architectural features with potential prognostic signifi-
cance in a large cohort of invasive breast carcinomas
NST and mixed NST/special subtype. Microarchitectural
features reflecting the geometry of tumour cell nests and
the extent of tumour-stroma interface were selected.
They included total nest number/perimeter and mean
nest size/perimeter/circularity/roundness.
Tumour arrangement in numerous small nests was
associated with axillary lymph node involvement and
lower BCSS probability. This prognostic association was
independent of tumour grade and size. The correlation
between number of nests and BCSS reached borderline
significant levels in grade 1 tumours, despite their small
number in this cohort that prevented confirmation of the
prognostic value of tumour size. Unlike lymph node in-
volvement, total nest perimeter was the microarchitectural
feature most significantly associated with survival, as
higher total nest perimeter was associated with a lower
BCSS. This association was only seen in the ER+/HER2–
subset. It was not only independent of traditional prog-
nostic parameters, but its strength was of a similar order
of magnitude to the strength of association of grade and
size with survival. High nest number in triple-negative
cases showed a suggestive association with distant metas-
tasis and shorter survival, but not with lymph node in-
volvement. Furthermore, in triple-negative tumours there
was a significant association between mean nest circularity
and distant metastasis and survival. As discussed below,
the difference in the type of microarchitectural features as
predictors of lymph node involvement versus survival
might reflect a corresponding pattern of invasion-
associated predisposition for lymphatic or haematogenous
spread. The differential prognostic ability of particular
microarchitectural features in different tumour subgroups
might reflect variance in other microenvironmental
interactions.
There are only a few studies applying DIA of tumour
microarchitectural features in breast cancer. Tumour
and stromal features in TMAs from two independent
cohorts of 576 breast cancer patients were analysed with
the use of a digital analysis package (C-Path) developed
by Beck et al. which implements a data-driven approach
with minimal user direction [22]. The feature with the
highest coefficient in their prognostic model was related
to the pattern of tumour-stroma interaction. High score,
which was associated with better outcome, was a measure
of large contiguous areas of tumour within large contigu-
ous areas of stroma, rather than thin cords of epithelium
infiltrating through stroma [22], in keeping with our find-
ing of favourable prognosis in tumours arranged in larger
nests. In a subsequent report of DIA with similar objectives
to our study, Wang et al. described a mathematical param-
eter, which integrated number and total perimeter of nests
in TMAs from 202 invasive ductal carcinomas and that
was shown to function as an independent prognostic factor
for 5-year disease-free survival [23]. Our prognostic associa-
tions of number of nests and total nest perimeter with
breast cancer-specific survival are entirely in keeping with
these data, arguing in favour of these microarchitectural
features as additional new prognostic parameters with the
potential to supplement grading for informed patient man-
agement. In a more recently published study from the same
group [24], Chen et al. used DIA to extract and evaluate
over 700 image features in a set of 230 breast cancer pa-
tients. Integration of traditional prognostic factors and
image features into a Cox proportional hazards model re-
sulted in four independent prognostic image features in-
cluding “TNs feature”, a measure of the morphologic
complexity of malignant epithelial architecture. The best
Fig. 6 Number of nest association with TTDM in grade 1 ER+/HER2– invasive carcinomas NST and mixed NST/special subtype. a 18-mm tumour
with nest number = 217; patient diagnosed with lung metastasis 31 months postoperatively; patient died from breast cancer at 36 months
postoperatively. b 25-mm tumour with nest number = 22; patient alive after 270 months of follow-up without metastasis
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discrimination was achieved in grade 2 tumours, where
identification of a low-risk subgroup was attained. The in-
teresting conceptual framework and results of this paper
are somewhat hampered by a relatively ambiguous defin-
ition of tumour architectural features and persistence of
large numbers of images intractable to the applied algo-
rithm. Using automated DIA in a large cohort of breast
cancer patients, Yuan’s group developed a mathematical
model that estimates cell diversity in histological sections.
High diversity was associated with poor prognosis in grade
3 tumours [25]. Although their approach is different, our
findings echo theirs, as high diversity corresponds with
smaller tumour groups interspersed with stromal elements,
whereas low diversity implies larger tumour groups without
intervening stroma.
We believe that our current study is the first to
address the differential prognostic impact of tumour
nest geometry in the four subgroups that derive from
combinations of ER and HER2 expression. The rationale
behind this approach was based on the evidence that ER
and HER2 expression profiles endow tumours with dif-
ferent biological properties. It also reflects our aim to
exploit microarchitectural features as potential dividers
of grade 2 ER+/HER2– tumours, a somewhat superfluous
group of invasive ductal carcinomas. It finally relates to
our aspiration for identifying features with prognostic
value in triple-negative cancers, a subgroup lacking reli-
able prognostic markers. To the extent of our know-
ledge, our study is also the first to deal with the
association between tumour nest microarchitecture and
axillary lymph node involvement.
Metastasis is a complex process comprising multiple
interactions that enable tumour cells to migrate through
the stromal microenvironment and gain access to the
lymphovascular compartment. The two main types of
cell migration described in vitro are single-cell migra-
tion/multicellular streaming, in which the cytoskeleton
of each cell acts independently for traction force gener-
ation, and collective cell migration and invasion, in
which the junctions between the cells are retained [26].
Several advantages of collective cell movement have
been proposed including high concentrations of auto-
crine concentrations of promigratory and proteolytic
molecules, protection of inner cells from immunological
attack, and promotion of invasion of less mobile but po-
tentially apoptosis-resistant clones [27, 28]. The signifi-
cance of the size of the group of collectively migrating
cells was addressed in an in-vitro model of epithelial cell
migration into fibronectin strips. It was shown that the
cell front was moving faster in thinner strips, whereas
cells in broader strips were moving in a more continu-
ous fashion [29]. More importantly than affecting the
mere velocity of tumour cell migration, different micro-
architectural arrangements have been shown to possess
different metastatic predilections, with single motile cells
entering either blood vessels or lymphatics, but collect-
ively moving cells preferentially entering lymphatics [15].
We found that in ER+/HER2– tumours mean nest
area, but not total nest perimeter, affects predisposition
for lymph node involvement, although it is not prognos-
tic for BCSS. On the other hand, total nest perimeter ra-
ther than mean nest area affects BCSS but not lymph
node status. This disparity is quite intriguing. For a given
nest size, a longer perimeter implies a more outspread
arrangement, with more tumour cells intimately contact-
ing the tumour stroma. For this reason, total tumour
nest perimeter can be considered as a more explicit
marker of the extent of tumour-stroma interface and
cross-talk. Our data indicate that this is the most highly
significant tumour microarchitectural predictor of sur-
vival, consistent with the previously proposed role of the
tumour-stroma interface in the pathogenesis of breast
cancer metastasis, and its promise as a therapeutic target
[30]. As noted above, the strength of association of total
nest perimeter with BCSS was of a similar order of mag-
nitude to the strength of association of grade and size
with BCSS. This finding highlights the potential of this
parameter as a clinically valuable independent prognos-
tic marker. It also implies that, with careful assessment
of whole sections, it might prove to be a prognostic
parameter stronger than grade and size for survival, as
grade and size were assessed in the tumour entirety
whereas microarchitectural features were only estimated
on the available TMA tumour snapshots. Obviously,
quantitative analysis on whole tumour sections might also
increase the odds and hazard ratios of other associations
described in this paper, and reveal “hotspots” with
clinical value.
The potency of stroma in affecting the phenotype and
physiological behaviour of malignant cells is highlighted by
findings such as upregulation of epithelial-mesenchymal
transition-associated proteins such as N-cadherin [31] and
Snail [32] at the tumour-stroma interface. Transforming
growth factor (TGF)β signalling around tumour margins
appears to be crucial in driving single-cell invasion and
haematogenous spread [15]. The details of this cross-talk
might explain our finding that particular microarchitec-
tural features display differential prognostic ability in
different tumour subgroups. For example, avian erythro-
blastosis oncogene B-2 (ErbB-2) signalling activates
epithelial-mesenchymal transition-promoting Rho family
guanosine triphosphates (GTPases), thus enhancing the
metastatic potential of breast cancer in experimental
settings [33]. From this observation, it can be hypothesised
that HER2– and HER2+ tumours might rely to a varying
degree on their extent of tumour-stroma interface.
We certainly take note of the prognostic associations
between mean nest roundness/circularity and lymph
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node involvement. Perhaps even more interestingly, we
notice the association between mean nest circularity and
TTDM/BCSS in triple-negative tumours, a subgroup of
breast cancers where prognostic markers are needed for
subclassification and oncological practice support [34].
However, as the used definition of circularity includes
both nest sphericity and smoothness, these findings need
more complex analysis of the tumour nest microgeometry.
This need is further highlighted in view of the relatively
spherical shape and smooth outline of singly infiltrating
tumour cells, the presence of which might be the predom-
inant underlying prognostic parameter in this setting.
Our paper has certain limitations that should be
addressed in subsequent studies. Analysis was carried
out in TMAs, which only partly disclose the tumour
entireness. This limitation is potentially more significant
for mixed tumours. As indicated above, studies in whole
tissue sections have the potential to reveal intratumoural
heterogeneity that might be crucial in refining the prog-
nostic significance of certain microarchitectural features.
The clinical implications of breast cancer heterogeneity
assessment with a digital methodology is elegantly dem-
onstrated in studies on the prognostic significance of the
spatial distribution of tumour infiltrating lymphocytes
[35, 36]. Another limitation was the relatively low
numbers of HER2+ and triple-negative cases. While cer-
tain associations and trends were observed in the latter,
larger numbers of cases are necessary for definite con-
clusions to be drawn. A further limitation is the use of a
relatively old cohort of patients, some of whom were
treated according to former guidelines. However, the
benefit of a long follow-up is obviously an invaluable
merit. A lesser weakness in our study was the variability
in the intensity of immunostaining. Although the vast
majority of included cases showed strong and uniform
pattern of cytokeratin 7/8 expression, there was certainly
a requirement for all cores to be visually evaluated by a
pathologist before and after the image analysis. Assessment
by a pathologist was also necessary to exclude occasional
normal ducts and ducts involved by ductal carcinoma
in situ (DCIS).
Conclusions
Taking into consideration the findings and data from
experimental platforms, the evidence suggests that
tumour arrangement in few large nests indicates a de-
creased metastatic potential, possibly related to low mo-
tility. On the other hand, arrangement in numerous
small nests or as single cells provides the tumour with
increased metastatic potential to regional lymph nodes,
which is theoretically related to increased availability of
and response to motility factors. An outstretched pattern
with extensive tumour-stroma interface bestows tu-
mours with a tendency for distant metastasis and
deriving increased likelihood of breast cancer-specific
death. This is conceptually related to co-occurrence of
additional factors, with TGFβ being a prime candidate.
We are currently in the process of correlating our histo-
morphometric data with expression profiles of selected
tumour motility-associated proteins and other microen-
vironmental components including tumour-infiltrating
lymphocytes.
The accordance of our findings with previous studies
together with our demonstration of highly concordant
data between the public domain and the commercial
software provides strong evidence for the validity and
genuine prognostic significance of tumour microarchi-
tectural feature analysis. Further validation studies, espe-
cially on whole tissue sections where the impact of
tumour heterogeneity and the potential significance of
hotspots could be suitably addressed, are required before
the argument for routine application of microarchitec-
tural feature quantification along grading is firmly estab-
lished. We strongly believe that this digital image
analysis approach deserves consideration, especially in
view of the high demand for cost-effective methods for
triaging breast cancer patients that are more likely to
benefit from chemotherapy.
Histological sections provide an ideal platform where
cancer can be studied within its native milieu, a clear
advantage over other methodologies, especially in view
of the cross-talk between malignant cells and their
microenvironment. We hope that this paper has the
potential to raise attention to the fact that, although
histological sections do not enjoy the advantage of in-
vitro systems in actively experimenting with the impact
of specific parameters in tumour progression, they have
the capacity to reveal spatial inter-relationships within
multiparametric real-life settings, as in tumours of indi-
vidual patients. It is exactly in the elucidation of such
complex systems where digital image analysis can play a
key role, not merely facilitating analysis but, in fact,
bringing to light correlations inaccessible to perception
and poorly denoted by semi-quantitative approaches.
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